On Monday, Shares of Gilead Sciences, Inc. (NASDAQ:GILD), lost -5.33% to $94.80.
Gilead Sciences declared that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for the investigational, once-daily single tablet regimen Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg) for the treatment of HIV-1 infection. The data presented in the MAA support the use of the regimen among adult and adolescent treatment-naïve individuals, virologically suppressed adults who switch regimens and adults with mild-to-moderate renal impairment.
The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union. If authorized, Genvoya would be Gilead’s first single tablet regimen to contain TAF.
TAF is a novel investigational nucleotide reverse transcriptase inhibitor (NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF), in addition to improvement in surrogate laboratory markers of renal and bone safety as contrast to TDF in clinical trials in combination with other antiretroviral agents.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions.
Shares of Exxon Mobil Corporation (NYSE:XOM), declined -0.87% to $72.59, during its last trading session, as falling crude prices put negative pressure on the oil sector Monday.
Fluctuating U.S. equity prices as well weak Chinese economic data is causing crude prices to fall in trading Monday.
Also hurting oil prices recently are comments from New York Federal Reserve President William Dudley suggesting that the U.S. Federal Reserve could raise interest rates sometime this year.
Oil prices have more than halved over the past 12 months as oversupply concerns have continued to cause oil prices to fall.
Exxon Mobil Corporation is an energy company. The Company is engaged in the exploration and production of crude oil and natural gas. The Company is involved in the manufacturing of petroleum products, and transportation and sale of crude oil, natural gas and petroleum products.
Shares of Medtronic PLC (NYSE:MDT), declined -3.01% to $64.53, during its last trading session.
Medtronic declared it has attained Lazarus Effect, a Campbell, Calif.-based and privately-held medical device company focused on acute ischemic stroke products that facilitate the capture and removal of clots. The acquisition is another example of the company`s commitment to its key growth strategy of therapy innovation.
The Lazarus Effect acquisition by Medtronic is an all-cash transaction of $100 million at closing.
The Lazarus CoverTM Cover(TM) device is an innovative differentiating technology that is complementary to Medtronic`s Solitaire(TM) stent retriever platform. This technology is designed to address clinical needs with a novel nitinol “mesh cover” that folds over a stent retriever device during clot retrieval and “candy wraps” the stent with the clot inside.
Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Finally, Hilton Worldwide Holdings Inc (NYSE:HLT), ended its last trade with -4.55% loss, and closed at $22.04.
Coffee and tea drinkers, rejoice. Hilton Worldwide Holdings declared an expanded partnership with The Coffee Bean & Tea Leaf®, the oldest and largest privately held specialty coffee and tea retailer in the United States. Guests at Hilton Hotels & Resorts, Curio – A Collection by Hilton, DoubleTree by Hilton and Embassy Suites by Hilton properties in the United States can select and discover brewed beverage flavors they love. Together, Hilton Worldwide and The Coffee Bean & Tea Leaf will deliver high-quality beverages through a partnership grounded in shared values of community, environmental responsibility and support of developing countries.
Now, guests can enjoy specialty drink combinations in participating properties’ lobbies, restaurants, lounges and gourmet markets – counting Herb N’ Kitchen, Made Market and E’Terie serving stations – as well as through brewed-to-order room service and at banquets, meetings and events.
Additionally, when patrons purchase a beverage, they will also be contributing to The Coffee Bean & Tea Leaf’s “Caring Cup” initiatives, which support charities, foundations and schools around the world.
Hilton Worldwide Holdings Inc. is a hospitality company. The Company comprises of approximately 4,322 hotels, resorts and timeshare properties comprising of 715,062 rooms in 94 countries and territories. The Company operates through three segments: management and franchise, ownership and timeshare.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
